Moderna's EBIT per Share for the
three
months ended in Mar. 2026 was CHF-2.63.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-6.33.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Moderna's EBIT per Share or its related term are showing as below:
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Moderna was -40.50% per year. The lowest was -76.90% per year. And the median was -40.90% per year.
XSWX:MRNA's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Moderna's EBIT for the
three
months ended in Mar. 2026 was CHF-1,037 Mil.
Moderna (XSWX:MRNA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Moderna EBIT per Share Related Terms
Moderna EBIT per Share Historical Data
* Premium members only.
The historical data trend for Moderna's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-6.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (XSWX:MRNA) has a EBIT per Share of CHF-6.33 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #999999 out of 1179 companies in the Biotechnology industry.
Is Moderna's EBIT per Share too high?
Moderna's current EBIT per Share is CHF-6.33. Based on the distribution chart, Moderna ranks #999999 out of 1179 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moderna has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's EBIT per Share compare to RPRX and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #999999 out of 1179 companies for EBIT per Share. This places Moderna in the lower half of its industry. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,179 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moderna and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current EBIT per Share is CHF-6.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (XSWX:MRNA) has a current EBIT per Share of CHF-6.33. The stock's GF Value™ is CHF18.28, compared to a current price of CHF57.81 — trading 216.2% above its estimated fair value. The current EBIT per Share is CHF-6.33. Moderna's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Moderna (XSWX:MRNA), the current EBIT per Share is CHF-6.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (XSWX:MRNA) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of CHF57.81 is trading 216.2% above its estimated GF Value™ of CHF18.28.
Key valuation signals for XSWX:MRNA:
EBIT per Share: CHF-6.33
GF Value™: CHF18.28 vs. price of CHF57.81 (216.2% above fair value)
No single metric tells the full story. See the XSWX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
62GF Score
Get the complete analysis for XSWX:MRNA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MRNA has been successfully added to your 
